MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$1.43 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$1.88B
Enterprise ValueHK$450.53M
Total Cash (Recent Filing)HK$1.38B
Total Debt (Recent Filing)HK$258.36M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line growth (399.4M in 2025, +8.7% YoY) signals sustained demand for the company’s cardiovascular offerings. Durable revenue expansion supports scale, improves bargaining with hospitals/distributors, and provides a base to absorb fixed costs as the firm pursues profitability over the medium term.
Solid Gross MarginA ~55% gross margin indicates strong product-level profitability and pricing power typical of differentiated medtech devices. High gross margins provide structural room to invest in R&D and commercial expansion, helping the company pursue profitable growth if operating costs are controlled over time.
Consumables-driven Revenue ModelA business model tied to devices plus recurring consumables creates revenue stickiness and predictable aftermarket sales. Procedure-driven consumable demand supports recurring cash flows and customer lock-in, underpinning long-term unit economics even if initial device adoption requires ongoing commercialization investment.
Bears Say
Sharp Rise In LeverageA large increase in debt to ~1.62B and debt/equity ~6.3x materially weakens the balance sheet. Elevated leverage raises refinancing and covenant risk, increases interest burden, and constrains strategic flexibility, especially hazardous while the company remains loss-making and pursuing growth initiatives.
Negative Free Cash FlowPersistent negative free cash flow (~-38.3M in 2025) means the company cannot consistently self-fund operations and investments. Over the medium term this requires external financing, which is more costly and risky given the higher leverage and ongoing losses, limiting durable financial resilience.
Widening Net LossesDespite revenue growth, a ~-33% net margin and deteriorating profitability indicate the company has not converted scale into earnings. Continued losses erode equity, complicate debt servicing, and prolong the path to sustainable profitability unless management executes material cost or mix improvements.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$1.43 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$1.88B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 79 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---